A research team at Kumamoto University has developed a new blood-based approach that could help detect breast cancer recurrence by looking beyond conventional genetic mutations and examining how DNA is packaged inside cells.

A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. This combination therapy induces irreparable DNA damage in cancer cells while also stimulating the body’s immune system to combat the disease.

A new study reveals that oncogenic signaling can reshape cancer cells not only by changing gene activity, but also by changing how cellular machinery reads the genetic code.

The University of Texas MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership during the Faculty Excellence Awards on August 20, 2026. The institution’s annual Celebration of Faculty Excellence honors faculty whose achievements advance UT MD Anderson's mission to end cancer and make a meaningful impact on patients and communities worldwide.

A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood.

Researchers used super-resolution microscopy to watch the cancer drug sunitinib move through living cells and measure its effects on the cell's internal infrastructure. Taking advantage of the drug's natural fluorescence, the team tracked its localization and found that it accumulates primarily in lysosomes, cellular compartments involved in recycling waste. As drug concentrations increased, the researchers observed progressive disruption of lysosomes, mitochondria, and the endoplasmic reticulum, three interconnected systems that help maintain cellular function and survival. The study, published in Biophotonics Discovery, provides new insight into the intracellular pharmacodynamics underlying both the therapeutic effects and toxicity of sunitinib cancer treatments, and demonstrates how advanced optical imaging can reveal drug-induced changes that are difficult to detect with conventional methods.